Cargando…

Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology

This paper aims to study the potential biological mechanism of Üstikuddus Sherbiti (ÜS) in the treatment of ischemic cerebrovascular diseases (ICVD) by the network pharmacology method. Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to obtain effective constituents of ÜS...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Aman, Aimaiti, Mutalifu, Tuerxun, Tuerhong, Amat, Raziye, Reheman, Ayinuer, Zhang, Min Fang, Memtily, Nassirhadjy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012636/
https://www.ncbi.nlm.nih.gov/pubmed/35432563
http://dx.doi.org/10.1155/2022/5581864
_version_ 1784687838204264448
author Gul, Aman
Aimaiti, Mutalifu
Tuerxun, Tuerhong
Amat, Raziye
Reheman, Ayinuer
Zhang, Min Fang
Memtily, Nassirhadjy
author_facet Gul, Aman
Aimaiti, Mutalifu
Tuerxun, Tuerhong
Amat, Raziye
Reheman, Ayinuer
Zhang, Min Fang
Memtily, Nassirhadjy
author_sort Gul, Aman
collection PubMed
description This paper aims to study the potential biological mechanism of Üstikuddus Sherbiti (ÜS) in the treatment of ischemic cerebrovascular diseases (ICVD) by the network pharmacology method. Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to obtain effective constituents of ÜS by screening eligible oral utilization, drug similarity, and blood-brain barrier permeability threshold. By drug target prediction and stroke treatment target mining, 2 target data sets were analyzed to find intersection targets and the corresponding constituents were used as active constituents. An active constituent target network and an effective constituent target network were constructed by using Cytoscape 3.7.2 software. Degree parameters of the effective constituent target network were analyzed to find important effective constituents and targets. Through protein-protein interaction (PPI) analysis/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, potential signaling pathways of ÜS in ischemic stroke were found out. AutoDock was used for molecular docking verification. A total of 90 active constituents of ÜS were screened out. There were 10 active constituents against ICVD, including quercetin, luteolin, kaempferol, and naringenin, and 10 important targets for anticerebral ischemia, namely, PIK3CA, APP, PIK3R1, MAPK1, MAPK3, AKT1, PRKCD, Fyn, RAC1, and NF-κB1. Based on the protein interaction network, the important targets of ÜS were significantly enriched in PI3K-Akt signaling pathway, neuroactive ligand-receptor interaction pathway, Ras signaling pathway, etc. ÜS in ICVD has characteristics like multiple targets, multiple approaches, and multiple pathways. Results of molecular docking showed that the active components in ICVD had a good binding ability with the key targets. Its main biological mechanism may be related to the PI3K-Akt and Ras-MAPK centered signaling pathway. Our study demonstrated that ÜS exerted the effect of treating ICVD by regulating multiple targets and multiple channels with multiple components through the method of network pharmacology and molecular docking.
format Online
Article
Text
id pubmed-9012636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90126362022-04-16 Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology Gul, Aman Aimaiti, Mutalifu Tuerxun, Tuerhong Amat, Raziye Reheman, Ayinuer Zhang, Min Fang Memtily, Nassirhadjy Evid Based Complement Alternat Med Research Article This paper aims to study the potential biological mechanism of Üstikuddus Sherbiti (ÜS) in the treatment of ischemic cerebrovascular diseases (ICVD) by the network pharmacology method. Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to obtain effective constituents of ÜS by screening eligible oral utilization, drug similarity, and blood-brain barrier permeability threshold. By drug target prediction and stroke treatment target mining, 2 target data sets were analyzed to find intersection targets and the corresponding constituents were used as active constituents. An active constituent target network and an effective constituent target network were constructed by using Cytoscape 3.7.2 software. Degree parameters of the effective constituent target network were analyzed to find important effective constituents and targets. Through protein-protein interaction (PPI) analysis/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, potential signaling pathways of ÜS in ischemic stroke were found out. AutoDock was used for molecular docking verification. A total of 90 active constituents of ÜS were screened out. There were 10 active constituents against ICVD, including quercetin, luteolin, kaempferol, and naringenin, and 10 important targets for anticerebral ischemia, namely, PIK3CA, APP, PIK3R1, MAPK1, MAPK3, AKT1, PRKCD, Fyn, RAC1, and NF-κB1. Based on the protein interaction network, the important targets of ÜS were significantly enriched in PI3K-Akt signaling pathway, neuroactive ligand-receptor interaction pathway, Ras signaling pathway, etc. ÜS in ICVD has characteristics like multiple targets, multiple approaches, and multiple pathways. Results of molecular docking showed that the active components in ICVD had a good binding ability with the key targets. Its main biological mechanism may be related to the PI3K-Akt and Ras-MAPK centered signaling pathway. Our study demonstrated that ÜS exerted the effect of treating ICVD by regulating multiple targets and multiple channels with multiple components through the method of network pharmacology and molecular docking. Hindawi 2022-04-08 /pmc/articles/PMC9012636/ /pubmed/35432563 http://dx.doi.org/10.1155/2022/5581864 Text en Copyright © 2022 Aman Gul et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gul, Aman
Aimaiti, Mutalifu
Tuerxun, Tuerhong
Amat, Raziye
Reheman, Ayinuer
Zhang, Min Fang
Memtily, Nassirhadjy
Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title_full Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title_fullStr Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title_full_unstemmed Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title_short Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology
title_sort study on the mechanism of üstikuddus sherbiti in ischemic cerebrovascular diseases: based on network pharmacology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012636/
https://www.ncbi.nlm.nih.gov/pubmed/35432563
http://dx.doi.org/10.1155/2022/5581864
work_keys_str_mv AT gulaman studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT aimaitimutalifu studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT tuerxuntuerhong studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT amatraziye studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT rehemanayinuer studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT zhangminfang studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology
AT memtilynassirhadjy studyonthemechanismofustikuddussherbitiinischemiccerebrovasculardiseasesbasedonnetworkpharmacology